Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 once-monthly oral HIV-1 PrEP vs emtricitabine/tenofovir
2025-520610-58-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of mk-8527 in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants With Adjudicated HIV-1 Infection, Number of Participants Who Experience At Least One Adverse Event and 1 more. Planned start Oct 2025; status: authorised.
02
Drugs
mk-8527
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2025-520610-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520610-58-00.